SELECT trial results

Adults aged 45 or older with cardiovascular disease and overweight or obesity, without diabetes.

Wegovy injection

Double-blind, placebo-controlled. Outcome includes cardiovascular death, non-fatal heart attack or non-fatal stroke.

Participants with a major cardiovascular event over 39.8 months of mean follow-up

Participants with a major cardiovascular event over 39.8 months of mean follow-up
Trial arm	Result
Semaglutide 2.4 mg	6.5%
Placebo	8.0%

Permanently stopped treatment due to adverse events
Trial arm	Result
Semaglutide 2.4 mg	16.6%
Placebo	8.2%

Safety. Adverse events led 16.6% of the semaglutide group and 8.2% of the placebo group to stop treatment permanently.